Louis J. Glunz III, Ph.D., was born on June 23, 1930. He founded Regis in 1956 and remains our Chairman today. Regis is a family-owned and operated business, a Glunz tradition since 1888. Dr. Glunz and his father would experiment together in a laboratory on the building’s third floor that […]

Regis Technologies is announcing their entry into the oncology market with the start up of the new Potent Compound Suite (PCS). The PCS allows Regis, a Chicago-based contract manufacturing organization (CMO), to target small molecule oncologicals and linker payload projects for antibody drug conjugates. Regis is a CMO operating a […]

As part of commissioning of the Regis’ Potent Compound Suite 1 (PCS1), an industrial hygiene monitoring was performed by Safebridge Consultants, Inc., on March 4 and 5 of 2015 with the purpose to evaluate the containment performance of the facility. Based on the occupational exposure limits (OELs) of the future […]

With almost two years of planning and construction complete, Regis Technologies’ Potent Compound Suite 1 (PCS1) is in testing. On March 4th and 5th, an expert independent lab, Safebridge Consultants, Inc., performed a surrogate powder study on PCS1, in order to evaluate the containment capability of the suite and to […]

Regis Technologies announced new potent compound capabilities this month for the development of oncology drug substances. Regis Technologies is proud to announce the commissioning and start up of their new Potent Compound Suite (PCS) for 2015. Regis is a contract manufacturing organization operating a 36,000 square foot, cGMP facility in […]

Regis’ Potent Compound Initiative is proceeding along well. Our Analytical Team underwent training last week on how to handle potent compounds with OEL’s (occupational exposure limit) down to 0.05 micrograms/m3 safely in the analytical labs. The Potent Compound Suite is expected to be commissioned at the end of the year, […]